Sugi Predict

Sugi Predict / Targets / NEK9

NEK9

Serine/threonine-protein kinase Nek9 · Q8TD19 · NEK9 on Sugi Atlas →

4,740 patent compounds predicted against NEK9, 3,878 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
R-406 R-406 (SCHEMBL1200144) 1.00 2/20
Fostamatinib Fostamatinib (SCHEMBL1201371) 1.00 2/20
SCHEMBL2627479 SCHEMBL2627479 0.92 2/20
SCHEMBL2627469 SCHEMBL2627469 0.91 2/20
SCHEMBL1383686 SCHEMBL1383686 0.89 2/20
SCHEMBL2627484 SCHEMBL2627484 0.84 2/20
R-406 R-406 (SCHEMBL1222514) 0.83 2/20
SCHEMBL2627481 SCHEMBL2627481 0.82 2/20
SCHEMBL2627480 SCHEMBL2627480 0.76 2/20
SCHEMBL2627470 SCHEMBL2627470 0.75 2/20
SCHEMBL2627048 SCHEMBL2627048 0.72 2/20
SCHEMBL2526082 SCHEMBL2526082 0.72 2/20
SCHEMBL2526159 SCHEMBL2526159 0.72 2/20
SCHEMBL2523179 SCHEMBL2523179 0.70 2/20
SCHEMBL2879117 SCHEMBL2879117 0.69 2/20
SCHEMBL2536722 SCHEMBL2536722 0.69 2/20
SCHEMBL2544982 SCHEMBL2544982 0.69 2/20
SCHEMBL2525389 SCHEMBL2525389 0.68 2/20
SCHEMBL2535479 SCHEMBL2535479 0.68 2/20
SCHEMBL2547766 SCHEMBL2547766 0.67 2/20

Clinical trials — most relevant to NEK9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2) PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors PHASE1/PHASE2RECRUITING
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants PHASE1COMPLETED
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer PHASE1RECRUITING
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer nanUNKNOWN
Genetics of Neonatal Encephalopathy and Related Disorders nanRECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Urinary Kallikrein and Hypertension: A Prospective Study nanCOMPLETED
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers nanCOMPLETED
Rostock International Parkinson's Disease Study (ROPAD) nanCOMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Sex Hormones and Blood PCSK9 Levels nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NEK9 binder may also engage these)

ProteinNameSimilarity
Q8K1R7 — 1.000 Q8K1R7 →
Q7ZZC8 — 0.997 Q7ZZC8 →
Q91ZY8 — 0.985 Q91ZY8 →
Q99KY4 — 0.984 Q99KY4 →
Q91VB2 — 0.984 Q91VB2 →
Q2HJE1 — 0.984 Q2HJE1 →
P25799 — 0.983 P25799 →
Q60629 — 0.983 Q60629 →
P70600 — 0.983 P70600 →
Q8C7M3 — 0.983 Q8C7M3 →
Q90XC2 — 0.983 Q90XC2 →
P97874 — 0.983 P97874 →
Q9C026 — 0.982 Q9C026 →
PTK2B Protein-tyrosine kinase 2-beta 0.982 landscape →
P13234 — 0.982 P13234 →
Q9Z2R9 — 0.982 Q9Z2R9 →
Q8RXT4 — 0.982 Q8RXT4 →
Q5RJI5 — 0.982 Q5RJI5 →
Q7TMQ7 — 0.982 Q7TMQ7 →
INPP5B Type II inositol 1,4,5-trisphosphate 5-phosphatase 0.982 landscape →
NFKB1 Nuclear factor NF-kappa-B p105 subunit 0.982 landscape →
Q69Z98 — 0.982 Q69Z98 →
Q6ZPR6 — 0.982 Q6ZPR6 →
B2DD29 — 0.981 B2DD29 →
GAK Cyclin-G-associated kinase 0.981 landscape →
BRSK2 Serine/threonine-protein kinase BRSK2 0.981 landscape →
Q2I6J0 — 0.981 Q2I6J0 →
E9PUQ8 — 0.981 E9PUQ8 →
D4A7V9 — 0.981 D4A7V9 →
WDR91 WD repeat-containing protein 91 0.981 landscape →